Sanofi offers $18.5 billion for Genzyme

genzsano.png By Julianne Pepitone, staff reporter


NEW YORK (CNNMoney.com) -- French pharmaceutical firm Sanofi-Aventis is stepping up the pressure on U.S. biotech firm Genzyme, going public with an $18.5 billion cash offer and hinting it may consider a hostile takeover if Genzyme refuses to talk.

Sanofi said it first made the offer July 29 but decided to go public after being rebuffed by Genzyme. Monday's announcement is aimed at getting Genzyme to the table, or at the very least, to bring the offer to shareholders, said Sanofi in a statement.

"We feel we are left with no choice but to take our compelling proposal directly to your shareholders by making its terms public," Sanofi chief executive Christopher Viehbacher said in a letter sent to Genzyme.

Genzyme rebuffed the offer. "It provides no new information and no improvement in price, and therefore fails to establish a basis for engagement by the Genzyme board," chief executive Henri Termeer said in a response letter to Sanofi.

Sanofi's letter detailed a months-long attempt to engage Genzyme in acquisition discussions. Genzyme, a bio-pharmaceutical company that makes products to help treat rare diseases and cancer, was apparently "unwilling even to meet" said Sanofi.

Sanofi first sent Cambridge, Mass.-based Genzyme a letter on July 29 offering to buy it for $69 per share in cash. That was a 38% premium over Genzyme's closing price on July 1.

Sanofi said Genzyme also rejected an Aug. 11 proposal as well without agreeing to a meeting.

"After our repeated requests, you agreed only to let our respective financial advisors hold a meeting of limited scope," Sanofi said.

Termeer reiterated the company's previous position, saying, "without exception, each member of the Genzyme board believes this is not the right time to sell the company ... your opportunistic takeover proposal does not begin to recognize the significant progress underway to rectify our manufacturing challenges or the potential for our new-product pipeline."

Sanofi, which makes vaccines and drugs, said it could help Genzyme reach across the globe. But it also alluded to the smaller company's ongoing problems. Genzyme was forced to close its manufacturing plant last year because of a viral contamination, and the company recently said it could take three to four years to resolve the issue fully.

"Your continued refusal to enter into constructive discussions will serve only to further delay the ability of your shareholders to receive the substantial value [of] our offer," the Sanofi letter warned.

Neither company was available for immediate comment.

In U.S. trading, shares of Sanofi (SNY) closed down 1% while Genzyme (GENZ, Fortune 500) gained 3.4%. To top of page

Frontline troops push for solar energy
The U.S. Marines are testing renewable energy technologies like solar to reduce costs and casualties associated with fossil fuels. Play
25 Best Places to find rich singles
Looking for Mr. or Ms. Moneybags? Hunt down the perfect mate in these wealthy cities, which are brimming with unattached professionals. More
Fun festivals: Twins to mustard to pirates!
You'll see double in Twinsburg, Ohio, and Ketchup lovers should beware in Middleton, WI. Here's some of the best and strangest town festivals. Play
Index Last Change % Change
Dow 16,805.41 127.51 0.76%
Nasdaq 4,483.72 30.93 0.69%
S&P 500 1,964.58 13.76 0.71%
Treasuries 2.27 -0.00 -0.09%
Data as of 11:11pm ET
Company Price Change % Change
Ford Motor Co 13.78 -0.62 -4.31%
Microsoft Corp 46.13 1.11 2.47%
Apple Inc 105.22 0.39 0.37%
Bank of America Corp... 16.72 0.12 0.72%
Yahoo! Inc 43.50 0.90 2.11%
Data as of 4:03pm ET

Sections

New York headlines took a straight forward and direct approach with NYC's Ebola news. More

The midterm elections are around the corner, and the economy remains a top concern. With unemployment down and inflation low, why do people still feel the economy stinks? More

Shares of Facebook recently topped $80. They've more than quadrupled from their post-IPO lows of two years ago. Can Mark Zuckerberg keep the momentum in mobile going? More

Using technology developed for the military and implemented in Iraq, schools have installed alarm systems that detect gunfire. More

If you're looking to fly this holiday season, the clock's ticking to get the best prices. More

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.